Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins

Drug Delivery

Volumn 20, Issue 8, 2013, Pages 356-363

  Wang, Ji ^a   Jia, Junting ^b   Liu, Jianping ^a   He, Hongliang ^a   Zhang, Wenli ^a   Li, Zhenghua ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

D rHDL; Drug leakage; Modification; Remodeling; Tumor targeting

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPOID S 100; LIPOSOME; MONOCHOLESTERYLSUCCINATE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SUCCINIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOMIMETICS; CANCER THERAPY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOMIMETIC MATERIALS; BREAST NEOPLASMS; CHOLESTEROL ESTERS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MCF-7 CELLS; MICE; MICE, INBRED ICR; PACLITAXEL; PARTICLE SIZE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; TISSUE DISTRIBUTION;

EID: 84885614782     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.834418     Document Type: Article

References (35)

1. Alessandro C, Luisa C, Bernardetta M, et al. (2012). LCAT cholesterol esterification is associated with the increase of ApoE/ApoA-I ratio during atherosclerosis progression in rabbit. J Physiol Biochem 68: 541-53.
2. Cao WM, Murao K, Imachi H, et al. (2004). A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 64: 1515-21. (Pubitemid 38235625)
3. Ding Y, Wang W, Feng MQ, et al. (2012). A biomimetic nanovectormediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33: 8893-905.
4. Eirini MT, Maria SB, Elisavet HF, et al. (2010). HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208: 3-9.
5. Gessner A, Lieske A, Paulke B, Muller R. (2002). Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm 54: 165-70. (Pubitemid 34919390)
6. Jae YS, Yoosoo Y, Paul H, et al. (2012). pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine 7: 2805-16.
7. Jain SK, Chaurasiya A, Gupta Y, et al. (2008). Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 25: 289-97. (Pubitemid 352025005)
8. Jia JT, Xiao Y, Liu JP, et al. (2012). Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J Pharm Sci 101: 2900-8.
9. Jie L, Li ZX, Jeffrey IZ, Fuyuhiko T. (2012). In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug delivery system: enhanced efficacy by folate modification. Nanomedicine: N.B.M 8: 12-20.
10. Kim SI, Shin D, Lee H, et al. (2009). Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol 50: 479-88.
11. Kistler P, Nitschmann H. (1962). Large scale production of human plasma fractions. Vox Sang 7: 414-24.
12. Lacko AG, Nair M, Paranjape S, et al. (2002). High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 22: 2045-9. (Pubitemid 34857021)
13. Lee PY, Zhang RZ, Li V, et al. (2012). Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation. Int J Nanomedicine 7: 731-7.
14. Li C, Cui J, Wang C, et al. (2008). Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 70: 657-65.
15. Liadaki KN, Liu T, Xu S, et al. (2000). Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. J Biol Chem 275: 21262-71.
16. Maha S, Olga BG, Elizabeth B, et al. (2008). Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 130: 107-14.
17. Marina GD, Kannan M, Sushant T, et al. (2012). Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 65: 649-62.
18. McConathy WJ, Nair MP, Paranjape S, et al. (2008). Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19: 183-8.
19. Mineo C, Philip WS. (2012). Functions of scavenger receptor class B, type I in atherosclerosis. Curr Opin Lipidol 23: 487-98.
20. Mooberry LK, Nair M, Paranjape S, et al. (2010). Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 18: 53-8.
21. Murakami T. (2012). Phospholipid nanodisc engineering for drug delivery systems. Biotechnol J 7: 762-7.
22. Nobecourt E, Davies M, Brown B, et al. (2007). The impact of glycation on apolipoprotein AI structure and its ability to activate lecithin: cholesterol acyltransferase. Diabetologia 50: 643-53. (Pubitemid 46215509)
23. Rader DJ. (2006). Molecular regulation of HDL metabolism and function: Implications for novel therapies. J Clin Investig 116: 3090-100. (Pubitemid 44878620)
24. Rensen PCN, de Vrueh RLA, Kuiper J, et al. (2001). Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47: 251-76. (Pubitemid 32324117)
25. Roosbeek S, Vanloo B, Duverger N, et al. (2001). Three arginine residues in apolipoprotein AI are critical for activation of lecithin: cholesterol acyltransferase. J Lipid Res 42: 31-40. (Pubitemid 32142858)
26. Sabnis N, Lacko A. (2012). Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv 3: 599-608.
27. Tufteland M, Ren G, Ryan R. (2008). Nanodisks derived from amphotericin B lipid complex. J Pharm Sci 97: 4425-32.
28. Wang L, Chen WZ, Wu MP. (2010). Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the HDL inflammatory index. Cytokine 49: 194-200.
29. Wei Z, Yuan S, Yan Z, et al. (2011). The potential of Pluronic polymeric micelles encapsulated with paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. Biomaterials 32: 5934-44.
30. Xu Y, Jin XF, Ping QN, et al. (2010). A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery. J Control Release 146: 299-308.
31. Yan H, Yong H, Xiang F, et al. (2011). Anti-tumor activity of biodegradable polymer-paclitaxel conjugate micelles on lewis lung cancer mice models. J Biomater Sci Polymer Ed 22: 1131-46.
32. Yuta Y, Yusuke K, Kenichi O, et al. (2011). PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm 412: 132-41.
33. Zhang MY, Jia JT, Liu JP, et al. (2012). A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J Pharm Sci 7: 364-73.
34. Zhang WL, He HL, Liu JP, et al. (2013). Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials 34: 306-19.
35. Zhang WL, Xiao Y, Liu JP, et al. (2011). Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanismin foam cell model. Int J Pharm 419: 314-21.